Portal de Periódicos da CAPES

Beta-Adrenergic Receptor Blockade Propranolol and Related Drugs

1967; American College of Physicians; Volume: 67; Issue: 6 Linguagem: Inglês

10.7326/0003-4819-67-6-1333

1539-3704

Stephen E. Epstein,

Hormonal and reproductive studies

Editorials1 December 1967Beta-Adrenergic Receptor Blockade Propranolol and Related DrugsSTEPHEN E. EPSTEIN, M.D., EUGENE BRAUNWALD, M.D., F.A.C.P.STEPHEN E. EPSTEIN, M.D.Search for more papers by this author, EUGENE BRAUNWALD, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-67-6-1333 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptPropranolol, the first beta-adrenergic receptor blocking agent to receive approval from the Food and Drug Administration for marketing, will soon be available for general use in the United States. Because of the mass of information that has accumulated relating to the physiological, metabolic, and clinical effects of this type of pharmacologic agent (1), great interest has developed in the clinical application of beta-adrenergic receptor inhibition. However, the widespread enthusiasm attendant upon the imminent availability of drugs that can specifically block beta receptors should be tempered. Although these agents have been shown to have considerable therapeutic efficacy, there is ample evidence...References1. EPSTEINBRAUNWALD SEE: Beta-adrenergic receptor blocking drugs. Mechanisms of action and clinical applications. New Eng. J. Med. 275: 1106, 1175, 1966. CrossrefMedlineGoogle Scholar2. EPSTEINROBINSONKAHLERBRAUNWALD SBFRLE: Effects of beta-adrenergic blockade on the cardiac response to maximal and submaximal exercise in man. J. Clin. Invest. 44: 1745, 1965. CrossrefMedlineGoogle Scholar3. EPSTEINBRAUNWALD SEE: The effect of beta adrenergic blockade on patterns of urinary sodium excretion: studies in normal subjects and in patients with heart disease. Ann. Intern. Med. 65: 20, 1966. LinkGoogle Scholar4. GRANTKEELANKERNOHANLEONARDNANCEKIEVILLSINCLAIR RHPRJJCLK: Multicentre trial of propranolol in angina pectoris. Amer. J. Cardiol. 18: 361, 1966. CrossrefMedlineGoogle Scholar5. WOLFSONHEINLEHERMANKEMPSULLIVANGORLIN SRAMVHGJMR: Propranolol and angina pectoris. Ibid., p. 345. Google Scholar6. SONNENBLICKBRAUNWALDWILLIAMSGLICK EHEJFG: Effects of exercise on myocardial force-velocity relations in intact unanesthetized man: relative roles of changes in heart rate, sympathetic activity, and ventricular dimensions. J. Clin. Invest. 44: 2051, 1965. CrossrefMedlineGoogle Scholar7. BRAUNWALD E (editor): Symposium on beta adrenergic receptor blockade. Amer. J. Cardiol. 18: 303, 1966. CrossrefMedlineGoogle Scholar8. PAULKHURST EAJW: Clinical problems of cardioversion. Amer. Heart J. 70: 248, 1965. CrossrefMedlineGoogle Scholar9. SEKIYAVAUGHAN WILLIAMS AEM: The effects of pronethalol, dichloroisoprenaline and disopyramide on the toxicity to the heart of ouabain and anaesthetics. Brit. J. Pharmacol. 21: 462, 1963. Google Scholar10. LUCCHESI BR: The effects of pronethalol and its dextro isomer upon experimental cardiac arrhythmias. J. Pharmacol. Exp. Ther. 148: 94, 1965. MedlineGoogle Scholar11. PARMLEYBRAUNWALD WWE: Comparative myocardial depressant and anti-arrhythmic properties of D-propranolol, DL-propranolol, and quinidine. J. Pharmacol. Exp. Ther. In press. Google Scholar12. SOMANIFLEMINGCHANLUM PJGGKBK: Antagonism of epinephrine-induced cardiac arrhythmias by 4-(2-isopropylamino-1-hydroxyethyl)-methanesulfonanilide (MJ-1999). J. Pharmacol. Exp. Ther. 151: 32, 1966. MedlineGoogle Scholar13. BALCONJEWITTDAVIESORAM RDEJPS: A controlled trial of propranolol in acute myocardial infarction. Lancet 2: 917, 1966. CrossrefGoogle Scholar14. CLAUSENFELSBYJORGENSENNIELSENROINSTRANGE JMFSBLJB: Absence of prophylactic effect of propranolol in myocardial infarction. Ibid., p. 920. Google Scholar15. STEPHENBATHBLAKEBLOOMBROWNFLEMINGFRANKLINFULTONJACKSONLECKIEMELROSETURNERTURNERTWORT SAJCSRARHAAJRMEWJAGJRRWRJ: Propranolol in acute myocardial infarction. A multicentric trial. Ibid., p. 1435. Google Scholar16. SEKIYAVAUGHAN WILLIAMS AEM: A comparison of the antifibrillatory actions and effects on intracellular cardiac potentials of pronethalol, disopyramide and quinidine. Brit. J. Pharmacol. 21: 473, 1963. Google Scholar17. TUTTLEINNES RRIR: Antagonism of ouabain-induced arrhythmias by nethalide. Pharmacologist 6: 165, 1964. Google Scholar18. LEVYRICHARDS JVV: Inotropic and metabolic effects of three beta-adrenergic receptor blocking drugs on isolated rabbit left atria. J. Pharmacol. Exp. Ther. 150: 361, 1965. MedlineGoogle Scholar19. BLINKS JR: Evaluation of the cardiac effects of several beta adrenergic blocking agents. Ann. N. Y. Acad. Sci. 139: 673, 1967. CrossrefMedlineGoogle Scholar20. COHENBRAUNWALD LSE: Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation 35: 847, 1967. CrossrefMedlineGoogle Scholar21. HONEYCHAMBERLAINHOWARD MDAJ: The effect of beta-sympathetic blockade on arterial oxygen saturation in Fallot's tetralogy. Circulation 30: 501, 1964. CrossrefMedlineGoogle Scholar22. ABRAMSONARKYWOEBER EARAKA: Effects of propranolol on the hormonal and metabolic responses to insulin-induced hypoglycaemia. Lancet 2: 1386, 1966. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: STEPHEN E. EPSTEIN, M.D.; EUGENE BRAUNWALD, M.D., F.A.C.P.Affiliations: Cardiology Branch National Heart Institute National Institutes of Health Bethesda, Md. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byLimitation of Work Performance in Normal Adult Males in the Presence of Beta-Adrenergic BlockadeLong-term propranolol therapy for angina pectorisHerz und Grosse GefässeCirculatory effects of practololHerz und Grosse Gefässe52 Factors That Can Affect Blood Glucose LevelsPhysiology and pharmacology of the coronary circulation and myocardium, particularly in relation to coronary artery diseaseAntihypertensive Agents 1962–1968Chapter 8 Angina Pectoris and Antianginal Agents 1 December 1967Volume 67, Issue 6Page: 1333-1337KeywordsDrug administrationDrug marketingDrugsFood and Drug Administration ePublished: 1 December 2008 Issue Published: 1 December 1967 PDF downloadLoading ...